Gulf Resources (GURE) Shares Surge on Strong Financial Results

Gulf Resources, Inc. (GURE)



Shares of GURE surged after the company delivered strong financial results compared to last year.


For the third quarter 2013, GURE posted net revenue of $32,935,277, an increase of approximately $8.4 million (or 34%) as compared to the same period in the prior year, and net income of $8,109,729, an increase of $3,996,513 (or approximately 97%) compared to the same period in 2012.



GURE is a leading provider of bromine, crude salt and a portfolio of various specialty chemicals throughout China. Its products are necessary components for China's flourishing oil and papermaking industries.


GURE operates through two wholly-owned subsidiaries, Shouguang City Haoyuan Chemical Company Limited, which primarily produces and distributes bromine and crude salt, and Shouguang Yuxin Chemical Industry Co., Limited, which focuses on manufacturing and selling chemical products.

More about Gulf Resources, Inc. (Nasdaq:GURE) at www.gulfresourcesinc.com



**

NanoViricides, Inc. (NNVC)



Dengue Fever is a mosquito-borne disease that, according to the World Health Organization, affects approximately 400 million people per year.

Dengue Hemorrhagic Fever, a subset of the disease that can occur after reinfection with another strain of the same virus, has a case fatality rate of up to 20%.


Before the opening bell on Monday, NNVC reported that the European Medicines Agency (EMA), has awarded orphan drug-designation to DengueCide(TM), its drug-candidate for the treatment of dengue and dengue hemorrhagic fever.


This orphan drug-designation enables several benefits for NNVC’s dengue drug-development program. These benefits include “protocol assistance,” or specific scientific advice that can speed up the drug-development program, as well as certain fee reductions, for drug-approval(s) under EMA.

More importantly, an approved orphan medicine in the EMA countries is expected to benefit from ten years of marketing exclusivity protection. An additional two years of exclusivity can be obtained if the drug-development has complied with an agreed pediatric investigation plan, with a total of twelve years of market exclusivity for a drug-that is approved for both adult and pediatric usage.


NNVC has previously reported that DengueCide was awarded orphan drug-status by the US FDA.


DengueCide is a nanoviricide(R) that has shown very high effectiveness in an animal model of dengue virus infection.